86 related articles for article (PubMed ID: 22691210)
1. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis.
Omair MA; Phumethum V; Johnson SR
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S55-9. PubMed ID: 22691210
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique.
Distler JH; Jordan S; Airo P; Alegre-Sancho JJ; Allanore Y; Balbir Gurman A; Caporali R; Caramaschi P; Carreira PE; Chizzolini C; Cutolo M; Tuncay Duruöz M; Farge-Bancel D; Hesselstrand R; Iannone F; De Keyser F; Kucharz EJ; Launay D; García de la Peña Lefebvre P; Lukacova O; Marasini B; Martinovic D; Marques Neto JF; Radic M; Rednic S; Riemekasten G; Rovensky J; Seidel MF; Senel S; Smith V; Sunderkötter C; Ton E; van Laar JM; Matucci-Cerinic M; Müller Ladner U; Distler O
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S40-5. PubMed ID: 21586217
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
6. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
[TBL] [Abstract][Full Text] [Related]
7. Arthritis in patients with systemic sclerosis.
Schmeiser T; Pons-Kühnemann J; Özden F; Müller-Ladner U; Dinser R
Eur J Intern Med; 2012 Jan; 23(1):e25-9. PubMed ID: 22153544
[TBL] [Abstract][Full Text] [Related]
8. Juvenile systemic sclerosis: experience from a tertiary care center from India.
Bagri NK; Raj D; Kaur J; Punia H; Saini I; Lodha R; Kabra SK
Rheumatol Int; 2017 Oct; 37(10):1687-1691. PubMed ID: 28831595
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience.
Castellví I; Elhai M; Bruni C; Airò P; Jordan S; Beretta L; Codullo V; Montecucco CM; Bokarewa M; Iannonne F; Balbir A; Hsu VM; Distler O; Matucci-Cerinic M; Allanore Y;
Semin Arthritis Rheum; 2020 Dec; 50(6):1489-1493. PubMed ID: 32165035
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
[TBL] [Abstract][Full Text] [Related]
11. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
12. Potential Effect of Tumor Necrosis Factor Inhibitors on Trabeculectomy With Mitomycin C for Patients With Juvenile Idiopathic Arthritis-Related Uveitic Glaucoma: A Retrospective Analysis.
Leinonen S; Kotaniemi K; Kivelä T; Majander A
JAMA Ophthalmol; 2015 Nov; 133(11):1323-8. PubMed ID: 26402863
[TBL] [Abstract][Full Text] [Related]
13. Potential use of TNF-α inhibitors in systemic sclerosis.
Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
[TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.
Griffiths B; Miles S; Moss H; Robertson R; Veale D; Emery P
J Rheumatol; 2002 Nov; 29(11):2371-8. PubMed ID: 12415594
[TBL] [Abstract][Full Text] [Related]
15. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases.
Johnson SR; Glaman DD; Schentag CT; Lee P
J Rheumatol; 2006 Jun; 33(6):1117-22. PubMed ID: 16622903
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.
Mori Y; Kuwahara Y; Chiba S; Itoi E
Mod Rheumatol; 2015 May; 25(3):431-4. PubMed ID: 25295919
[TBL] [Abstract][Full Text] [Related]
18. How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal study.
Minnock P; McKee G; Bresnihan B; FitzGerald O; Veale DJ
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1597-603. PubMed ID: 24966144
[TBL] [Abstract][Full Text] [Related]
19. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature.
Colaci M; Giuggioli D; Vacchi C; Lumetti F; Iachetta F; Marcheselli L; Federico M; Ferri C
Autoimmun Rev; 2014 Feb; 13(2):132-7. PubMed ID: 24103404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
